Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-930 in Idiopathic Pulmonary Fibrosis
NCT01203943Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Jan 2011
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of tanzisertib in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Celgene Corporation. Primary endpoint: Safety at Week 4. Started Jan 2011; status: terminated.
02
Drugs
tanzisertib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01203943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01203943.